ENTA — ENANTA PHARMACEUTICALS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1177648 ·
Last close
$8.69
Market Cap
$253.10M
52W High
$17.15
52W Low
$8.60
ADV30
263,240
Next earnings
2027-02-08
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | — | — | — | — | — | — | — |
| Jun 2026 | 14,359,000 | — | -17,236,000 | -19,501,000 | 296,870,000 | 33,419,000 | 195,802,000 |
| Mar 2026 | 17,159,000 | — | -11,852,000 | -13,091,000 | 314,704,000 | 34,928,000 | 198,117,000 |
| Dec 2025 | 18,615,000 | — | -11,253,000 | -11,938,000 | 329,503,000 | 37,437,000 | 202,912,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-35,316,000
Investing CF
$-19,055,000
Financing CF
$42,978,000
CapEx
$-1,623,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.41
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-449,459,000
Inventory
—
Receivables
$6,534,000
ST Investments
$156,087,000
EBIT TTM
$-50,215,000
Pretax Income TTM
$-63,131,000
Interest Exp TTM
$12,916,000
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$65,258,000
EBITDA
$-53,819,000
Free Cash Flow
$-22,656,876
Enterprise Value
$369,999,200
Total Cash
$189,506,000
Total Debt
$182,040,000
Shares Out
29,125,402
Trailing EPS
$-2.42
Book Value
$3.47
ROE
-70.1%
ROA
-12.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Sep 2025 | 65,324,000 | -85,349,000 | -81,889,000 | 280,732,000 | 216,015,000 | 64,717,000 | -19,272,000 |
| Sep 2024 | 67,635,000 | -121,691,000 | -116,045,000 | 376,652,000 | 247,838,000 | 128,814,000 | -78,764,000 |
| Sep 2023 | 79,204,000 | -137,207,000 | -133,816,000 | 462,275,000 | 245,540,000 | 216,735,000 | -103,154,000 |
| Sep 2022 | 86,160,000 | -123,844,000 | -121,755,000 | 375,410,000 | 54,076,000 | 321,334,000 | -84,782,000 |
TTM Snapshot
Revenues TTM
$65,258,000
NetIncome TTM
$-63,230,000
OpCashFlow TTM
—
Assets (Latest)
$296,870,000
Forward EPS
$-2.35
Max Pain — expiry 2027-04-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $15.00 · spot: $8.23 · call volume: 1 · put volume: 103
Expected Move to 2027-04-16:
±$5.46
(66.40%) —
implied range
$2.76 –
$13.69
· ATM straddle on $10.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CAMP | Camp4 Therapeutics Corp | $251.02M | $4.00 | — |
| NWBO | NORTHWEST BIOTHERAPEUTICS INC | $250.73M | $0.15 | — |
| PRE | Prenetics Global Ltd | $248.19M | $16.33 | — |
| QTTB | Q32 Bio Inc. | $258.24M | $8.63 | — |
| TTRX | Turn Therapeutics Inc. | $261.40M | $8.55 | — |
News headlines (Yahoo Finance, 1h cache)
Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Misses Revenue Estimates
2026-11-16 21:10 · Yahoo
Enanta Pharmaceuticals: Fiscal Q4 Earnings Snapshot
2026-11-16 21:08 · Yahoo
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2026
2026-11-16 21:01 · Yahoo
Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-11-04 12:00 · Yahoo
Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. After 23 Years of Company Leadership
2026-10-28 11:00 · Yahoo
Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV)
2026-10-26 11:00 · Yahoo
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026
2026-10-13 11:00 · Yahoo
Enanta Pharmaceuticals to Participate in September Investor Conferences
2026-09-01 11:00 · Yahoo
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates
2026-08-10 21:10 · Yahoo
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026
2026-08-10 20:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.